日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

新辅助双重阻断治疗HER2阳性乳腺癌的真实世界疗效：肿瘤生物学和病理完全缓解的作用

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm15062217
Bayramgil, Ayberk; Yücel, Mehmet Haluk; Turkoglu, Ezgi; Guren, Ali Kaan; Kemik, Fatih; Ulufer, Bedirhan; Çakan Demirel, Burçin; Yildiz, Anil; Sacli, Omer; Ercin, Eda; Demircan, Nazım Can; Kinikoglu, Oguzcan; Lacin, Sahin; Bilici, Ahmet; Altintas, Yunus Emre; Ozcelik, Melike
肿瘤免疫
HER2
肿瘤
乳腺癌
发表日期：2026
文献求助 收藏

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

阿比特龙或恩扎卢胺治疗的转移性激素敏感性前列腺癌（mHSPC）患者中，PSA最低值出现时间、放射学进展和PSA进展之间的关联

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm15010386
Ozkerim, Ugur; Kinikoglu, Oguzcan; Isik, Deniz; Altintas, Yunus Emre; Ay Ersoy, Seval; Surmeli, Heves; Odabas, Hatice; Basoglu, Tugba; Turan, Nedim
肿瘤
肿瘤免疫
PSA
前列腺癌
免疫/内分泌
发表日期：2026
文献求助 收藏

Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis

免疫治疗期间抗生素暴露对转移性肾细胞癌患者生存结局的影响：一项基于真实世界IMDC风险分层分析的研究

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm15051853
Oksuz, Sila; Kinikoglu, Oguzcan; Ozkerim, Ugur; Isik, Deniz; Surmeli, Heves; Ay, Seval; Odabas, Hatice; Turan, Nedim
肿瘤
MDC
肿瘤免疫
肾癌
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

GRIm评分与晚期恶性黑色素瘤患者对纳武利尤单抗单药治疗反应的相关性

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-025-06411-7
Oksuz, Sila; Kinikoglu, Oguzcan; Ozkerim, Ugur; Isik, Deniz; Surmeli, Heves; Ay, Seval; Gundogdu, Utku Donem; Basoglu, Tugba; Odabas, Hatice; Turan, Nedim
黑色素瘤
发表日期：2026
文献求助 收藏

Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

CEA动态变化和全身炎症标志物在接受一线化疗的HER2阳性转移性结直肠癌患者中的意义：一项真实世界队列研究

期刊:Medicina-Lithuania
影响因子:2.4
doi:10.3390/medicina62010099
Ozkerim, Ugur; Kinikoglu, Oguzcan; Oksuz, Sila; Isik, Deniz; Altintas, Yunus Emre; Yildirim, Sedat; Akdag, Goncagul; Surmeli, Heves; Odabas, Hatice; Basoglu, Tugba; Turan, Nedim
肿瘤
肠癌
炎症
肿瘤免疫
HER2
炎症/感染
发表日期：2026
文献求助 收藏

Cytotoxic effect of famotidine in breast adenocarcinoma cells line

法莫替丁对乳腺腺癌细胞系的细胞毒性作用

期刊:
影响因子:
doi:10.14744/nci.2026.55899
Kaskal, Mert; Kinikoglu, Oguzcan; Zelhof, George; Bilir, Emine Kubra
细胞生物学
肿瘤
毒理研究
肿瘤免疫
发表日期：2026
文献求助 收藏

Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

利用系统性炎症标志物构建基于机器学习的纳武利尤单抗免疫治疗患者预后模型：一项真实世界队列研究

期刊:Journal of Personalized Medicine
影响因子:3
doi:10.3390/jpm16010008
Ozkerim, Ugur; Isik, Deniz; Kinikoglu, Oguzcan; Oksuz, Sila; Altintas, Yunus Emre; Akdag, Goncagul; Yildirim, Sedat; Basoglu, Tugba; Surmeli, Heves; Odabas, Hatice; Turan, Nedim
炎症/感染
Immunology/Inflammation
炎症
免疫/内分泌
发表日期：2025
文献求助 收藏

Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

三阴性顶泌癌：最大规模队列研究揭示其独特的生物学特性和生存优势

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm14197103
Basoglu, Tugba; Ozkerim, Ugur; Oksuz, Sila; Kinikoglu, Oguzcan; Yildirim, Sedat; Kokten, Sermin; Surmeli, Heves; Isik, Deniz; Sever, Ozlem Nuray; Ay Ersoy, Seval; Odabas, Hatice; Turan, Nedim
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

家族史和个人病史对酪氨酸激酶抑制剂（TKIs）治疗非小细胞肺癌（NSCLC）疗效的影响

期刊:Healthcare
影响因子:2.7
doi:10.3390/healthcare13151810
Surmeli, Heves; Turkoglu, Ezgi; Isik, Deniz; Kinikoglu, Oguzcan; Altintas, Yunus Emre; Ozkerim, Ugur; Oksuz, Sila; Basoglu, Tugba; Odabas, Hatice; Turan, Nedim
肺癌
肿瘤
肿瘤免疫
信号转导
CLC
细胞生物学
发表日期：2025
文献求助 收藏

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

免疫组化评估的HER2状态对接受曲妥珠单抗-美坦新治疗的转移性乳腺癌患者治疗反应的影响

期刊:Medicina-Lithuania
影响因子:2.4
doi:10.3390/medicina61050819
Oksuz, Sila; Kinikoglu, Oguzcan; Ozkerim, Ugur; Altintas, Yunus Emre; Isik, Deniz; Surmeli, Heves; Odabas, Hatice; Ay, Seval; Basoglu, Tugba; Turan, Nedim
肿瘤
IHC
HER2
肿瘤免疫
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏